FSE sequence was less sensitive to mild cartilage abnormality but useful in detecting moderate to severe abnormality and in evaluating the degree of articular cartilage abnormality.
SummaryA 36-month observational study compared the incidence of unaffected side hip fracture in Japanese female osteoporosis patients with a history of hip fracture between 173 patients receiving risedronate and 356 risedronate-untreated controls. New hip fractures were significantly less frequent in the risedronate group, suggesting a preventive effect in high-risk patients.IntroductionThe purpose of this study was to investigate the preventive effect of risedronate on second hip fracture immediately following a first hip fracture in Japanese female osteoporosis patients with unilateral hip fracture.MethodsWe conducted a prospective matched cohort study in 184 patients treated with risedronate and 445 patients not receiving risedronate after discharge from hospital. Both groups were followed-up for 36 months, and the incidence of unaffected side hip fracture and the frequency of adverse events were assessed.ResultsEfficacy could be investigated in 173 patients from the risedronate group and 356 patients from the control group. Hip fracture was detected in 5 and 32 patients, respectively. Kaplan–Meier estimates of the 36-month fracture incidence were 4.3% in the risedronate group and 13.1% in the control group (P = 0.010, log-rank test). The hazard ratios (95% confidence intervals) obtained by univariate and multivariate analysis were 0.310 (0.121–0.796) and 0.218 (0.074–0.639), respectively, indicating a significantly lower incidence of unaffected side hip fracture in the risedronate group. Adverse events occurred in 38 patients (48 events) from the risedronate group and 94 patients (108 events) from the control group, with serious adverse events in 21 patients (26 events) and 78 patients (88 events), respectively.ConclusionsNo significant differences were observed between the two groups. The incidence of unaffected side hip fracture was significantly lower in the risedronate group. Accordingly, risedronate may have a preventive effect on hip fracture in high-risk Japanese female osteoporosis patients for fracture with a history of unilateral hip fracture.
It would be a revolutionary idea to interpose unresorbable osteoconductive HA at bone and bone cement interface by expecting chemical bonding of HA with bone and osteoconduction forever to prevent radiolucent line and loosening. As a surgical procedure, less than two layers of HA granules of 300 to 500 micron in diameter were smeared on the bone surface just before the cement insertion (Interface Bioactive Bone Cement : IBBC). In animal experiments, at one week, bone ingrowth began into one to two layers of HA granules. At two to three weeks, bone ingrowth completed. The bonding strength in the case of IBBC without anchor holes at six weeks attained to 50% of non-IBBC and IBBC with anchor holes and showed the same tendency as HA coating on the smooth surface. In clinical cases, the majority of HA granules were incorporated into dense cortical bone and cancellous bone connected to adjacent dense cortical bone and cancellous bone, respectively. The shape and sizes of HA granules were not changed at 17 years. In conventional bone cement (Non-IBBC) and cementless fixation, the spaces will appear at the bone interface due to aging of bone. As unresorbable crystalline HA is used in IBBC and HA is osteoconductive, at present enduring osteoconduction could be expected in only IBBC.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.